{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:35:23Z","timestamp":1792614923465,"version":"4.5.0"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.msard.2024.105830","type":"journal-article","created":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T06:01:55Z","timestamp":1724047315000},"page":"105830","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Safety of high efficacy therapies in older people with Multiple Sclerosis: A real-world evidence study"],"prefix":"10.1016","volume":"90","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5866-2419","authenticated-orcid":false,"given":"Berenice","family":"Silva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Casales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia Burbano","family":"Donoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Varela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"Heriz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimena","family":"M\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2024.105830_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104465","article-title":"Shared decision making in the treatment of multiple sclerosis: a consensus based on Delphi methodology","volume":"70","author":"Alonso","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2024.105830_bib0002","article-title":"Achieving no evidence of disease activity-3 in highly active multiple sclerosis patients treated with cladribine and monoclonal antibodies","volume":"9","author":"Alonso","year":"2023","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2024.105830_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104935","article-title":"Evaluation of the use of high-efficacy treatments (HETs) in patients with relapsing-remitting multiple sclerosis in Argentina","volume":"79","author":"Alonso","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2024.105830_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104941","article-title":"Real world study of ocrelizumab in multiple sclerosis: Kuwait experience","volume":"79","author":"Alroughani","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.msard.2024.105830_bib0005","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/ana.410310317","article-title":"Revised estimate of the prevalence of multiple sclerosis in the United States","volume":"31","author":"Anderson","year":"1992","journal-title":"Ann. Neurol."},{"issue":"19","key":"10.1016\/j.msard.2024.105830_bib0006","doi-asserted-by":"crossref","first-page":"e2232","DOI":"10.1212\/WNL.0000000000007451","article-title":"Natalizumab-associated progressive multifocal leukoencephalopathy in Germany","volume":"92","author":"Blankenbach","year":"2019","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.msard.2024.105830_bib0007","doi-asserted-by":"crossref","first-page":"e1041","DOI":"10.1212\/WNL.0000000000010135","article-title":"Initial high-efficacy disease-modifying therapy in multiple sclerosis: a nationwide cohort study","volume":"95","author":"Buron","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2024.105830_bib0008","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.829331","article-title":"Late-onset MS: disease course and safety-efficacy of DMTS","volume":"13","author":"Buscarinu","year":"2022","journal-title":"Front. Neurol."},{"issue":"6","key":"10.1016\/j.msard.2024.105830_bib0009","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1136\/jnnp-2019-322326","article-title":"Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP)","volume":"91","author":"Butzkueven","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatr."},{"key":"10.1016\/j.msard.2024.105830_bib0010","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1207617","article-title":"Aging in multiple sclerosis: from childhood to old age, etiopathogenesis, and unmet needs: a narrative review","volume":"14","author":"Capasso","year":"2023","journal-title":"Front. Neurol."},{"issue":"9856","key":"10.1016\/j.msard.2024.105830_bib0011","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","article-title":"Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial","volume":"380","author":"Cohen","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2024.105830_bib0012","doi-asserted-by":"crossref","DOI":"10.1177\/17562864231194823","article-title":"Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study","volume":"16","author":"Coles","year":"2023","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"9856","key":"10.1016\/j.msard.2024.105830_bib0013","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","article-title":"Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial","volume":"380","author":"Coles","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2024.105830_bib0014","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.msard.2018.11.021","article-title":"Safety of cladribine tablets in the treatment of patients with multiple sclerosis: an integrated analysis","volume":"29","author":"Cook","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"5","key":"10.1016\/j.msard.2024.105830_bib0015","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J. Chronic Dis."},{"issue":"1","key":"10.1016\/j.msard.2024.105830_bib0016","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00415-020-10362-z","article-title":"Rituximab for the treatment of multiple sclerosis: a review","volume":"269","author":"Chisari","year":"2022","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2024.105830_bib0017","doi-asserted-by":"crossref","first-page":"871","DOI":"10.3389\/fneur.2018.00871","article-title":"A systematic assessment of prevalence, incidence and regional distribution of multiple sclerosis in Bavaria from 2006 to 2015","volume":"9","author":"Daltrozzo","year":"2018","journal-title":"Front. Neurol."},{"issue":"9","key":"10.1016\/j.msard.2024.105830_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102893","article-title":"Immunosenescence in multiple sclerosis: the identification of new therapeutic targets","volume":"20","author":"Dema","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.msard.2024.105830_bib0019","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1112193","article-title":"Results of treatment with alemtuzumab in a Spanish cohort of patients with multiple sclerosis in the real world: the RealMS study","volume":"14","author":"Eichau","year":"2023","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2024.105830_bib0020","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1471-2318-13-32","article-title":"Assessment of vaccine candidates for persons aged 50 and older: a review","volume":"13","author":"Eilers","year":"2013","journal-title":"BMC Geriatr."},{"issue":"4","key":"10.1016\/j.msard.2024.105830_bib0021","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000719","article-title":"Ocrelizumab initiation in patients with MS: a multicenter observational study","volume":"7","author":"Ellwardt","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2024.105830_bib0022","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1379538","article-title":"Managing multiple sclerosis in individuals aged 55 and above: a comprehensive review","volume":"15","author":"Fernandez","year":"2024","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.msard.2024.105830_bib0023","doi-asserted-by":"crossref","first-page":"54","DOI":"10.5014\/ajot.58.1.54","article-title":"Concerns about the future among older adults with multiple sclerosis","volume":"58","author":"Finlayson","year":"2004","journal-title":"Am. J. Occup. Ther."},{"issue":"4","key":"10.1016\/j.msard.2024.105830_bib0024","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1177\/1352458520942201","article-title":"Progressive multifocal leukoencephalopathy on dimethyl fumarate with preserved lymphocyte count but deep T-cells exhaustion","volume":"27","author":"Garcia","year":"2021","journal-title":"Mult. Scler."},{"issue":"3","key":"10.1016\/j.msard.2024.105830_bib0025","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1136\/jnnp.2009.187666","article-title":"Progressive multifocal leukoencephalopathy in individuals with minimal or occult immunosuppression","volume":"81","author":"Gheuens","year":"2010","journal-title":"J. Neurol. Neurosurg. Psychiatr."},{"issue":"5","key":"10.1016\/j.msard.2024.105830_bib0026","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa0902533","article-title":"A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis","volume":"362","author":"Giovannoni","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.msard.2024.105830_bib0027","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/ni.2588","article-title":"Understanding immunosenescence to improve responses to vaccines","volume":"14","author":"Goronzy","year":"2013","journal-title":"Nat. Immunol."},{"issue":"8","key":"10.1016\/j.msard.2024.105830_bib0028","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11910-017-0771-9","article-title":"Immunosenescence: the role of aging in the predisposition to neuro-infectious complications arising from the treatment of multiple sclerosis","volume":"17","author":"Grebenciucova","year":"2017","journal-title":"Curr. Neurol. Neurosci. Rep."},{"issue":"1","key":"10.1016\/j.msard.2024.105830_bib0029","first-page":"100","article-title":"A 60-year follow-up of the incidence and prevalence of multiple sclerosis in Hordaland County, Western Norway","volume":"87","author":"Grytten","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatr."},{"issue":"5","key":"10.1016\/j.msard.2024.105830_bib0030","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1001\/jamaneurol.2018.4905","article-title":"Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis","volume":"76","author":"Harding","year":"2019","journal-title":"JAMA Neurol."},{"issue":"6","key":"10.1016\/j.msard.2024.105830_bib0031","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus teriflunomide in multiple sclerosis","volume":"383","author":"Hauser","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.msard.2024.105830_bib0032","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.msard.2024.105830_bib0033","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1177\/13524585221079731","article-title":"Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years","volume":"28","author":"Hauser","year":"2022","journal-title":"Mult. Scler."},{"issue":"16","key":"10.1016\/j.msard.2024.105830_bib0034","doi-asserted-by":"crossref","first-page":"e1546","DOI":"10.1212\/WNL.0000000000012700","article-title":"Safety of ocrelizumab in patients with relapsing and primary progressive multiple sclerosis","volume":"97","author":"Hauser","year":"2021","journal-title":"Neurology"},{"issue":"11\u201312","key":"10.1016\/j.msard.2024.105830_bib0035","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1177\/13524585231195346","article-title":"Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: the ALITHIOS open-label extension","volume":"29","author":"Hauser","year":"2023","journal-title":"Mult. Scler."},{"issue":"51\u201352","key":"10.1016\/j.msard.2024.105830_bib0036","first-page":"879","article-title":"Interdisciplinary risk management in the treatment of multiple sclerosis","volume":"113","author":"Havla","year":"2016","journal-title":"Dtsch Arztebl. Int."},{"issue":"1\u20132","key":"10.1016\/j.msard.2024.105830_bib0037","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jns.2010.09.012","article-title":"Decisions on multiple sclerosis immunotherapy: new treatment complexities urge patient engagement","volume":"306","author":"Heesen","year":"2011","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2024.105830_bib0038","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211019574","article-title":"Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies","volume":"14","author":"Iaffaldano","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"3","key":"10.1016\/j.msard.2024.105830_bib0039","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1080\/14737175.2021.1886082","article-title":"Considering patient age when treating multiple sclerosis across the adult lifespan","volume":"21","author":"Jakimovski","year":"2021","journal-title":"Expert. Rev. Neurother."},{"issue":"10","key":"10.1016\/j.msard.2024.105830_bib0040","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1007\/s00415-015-7842-0","article-title":"High incidence and increasing prevalence of multiple sclerosis in British Columbia, Canada: findings from over two decades (1991-2010)","volume":"262","author":"Kingwell","year":"2015","journal-title":"J. Neurol."},{"issue":"10","key":"10.1016\/j.msard.2024.105830_bib0041","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1007\/s40263-018-0564-y","article-title":"Cancer risk in patients with multiple sclerosis: potential impact of disease-modifying drugs","volume":"32","author":"Lebrun","year":"2018","journal-title":"CNS Drugs"},{"key":"10.1016\/j.msard.2024.105830_bib0042","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102572","article-title":"Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis","volume":"46","author":"Leist","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2024.105830_bib0043","article-title":"Alemtuzumab treatment in real clinical practice: experience in a multicenter cohort","volume":"75","author":"Lopez-Real","year":"2023","journal-title":"Mult. Scler. Relat. Disord.s"},{"issue":"4","key":"10.1016\/j.msard.2024.105830_bib0044","doi-asserted-by":"crossref","first-page":"e501","DOI":"10.1212\/WNL.0000000000011219","article-title":"Cancer incidence and mortality rates in multiple sclerosis: a matched cohort study","volume":"96","author":"Marrie","year":"2021","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.msard.2024.105830_bib0045","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1177\/1352458514564489","article-title":"A systematic review of the incidence and prevalence of cancer in multiple sclerosis","volume":"21","author":"Marrie","year":"2015","journal-title":"Mult. Scler."},{"issue":"6","key":"10.1016\/j.msard.2024.105830_bib0046","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1212\/WNL.0b013e3181cf6ec0","article-title":"The rising prevalence and changing age distribution of multiple sclerosis in Manitoba","volume":"74","author":"Marrie","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2024.105830_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104059","article-title":"A real world multi center study on efficacy and safety of natalizumab in Indian patients with multiple sclerosis","volume":"66","author":"Mathew","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2024.105830_bib0048","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2023.578066","article-title":"Predictors of hypogammaglobulinemia and serious infections among patients receiving ocrelizumab or rituximab for treatment of MS and NMOSD","volume":"377","author":"Mears","year":"2023","journal-title":"J. Neuroimmunol."},{"issue":"8","key":"10.1016\/j.msard.2024.105830_bib0049","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1177\/1352458518775550","article-title":"Aging and lymphocyte changes by immunomodulatory therapies impact PML risk in multiple sclerosis patients","volume":"24","author":"Mills","year":"2018","journal-title":"Mult. Scler."},{"issue":"3","key":"10.1016\/j.msard.2024.105830_bib0050","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2024.105830_bib0051","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102815","article-title":"Multiple sclerosis and aging: comorbidity and treatment challenges","volume":"50","author":"Ostolaza","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2024.105830_bib0052","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.685139","article-title":"Identification of the immunological changes appearing in the CSF during the early immunosenescence process occurring in multiple sclerosis","volume":"12","author":"Picon","year":"2021","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.msard.2024.105830_bib0053","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.msard.2024.105830_bib0054","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/ene.15142","article-title":"Ocrelizumab treatment in multiple sclerosis: a Danish population-based cohort study","volume":"29","author":"Pontieri","year":"2022","journal-title":"Eur. J. Neurol."},{"issue":"12","key":"10.1016\/j.msard.2024.105830_bib0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0168376","article-title":"Natalizumab-related progressive multifocal leukoencephalopathy in multiple sclerosis: findings from an Italian Independent Registry","volume":"11","author":"Prosperini","year":"2016","journal-title":"PLoS ONE"},{"issue":"5","key":"10.1016\/j.msard.2024.105830_bib0056","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1007\/s13365-017-0561-9","article-title":"Age as a risk factor for early onset of natalizumab-related progressive multifocal leukoencephalopathy","volume":"23","author":"Prosperini","year":"2017","journal-title":"J. Neurovirol."},{"issue":"8","key":"10.1016\/j.msard.2024.105830_bib0057","doi-asserted-by":"crossref","first-page":"713","DOI":"10.2217\/imt-2017-0178","article-title":"Consequences of B-cell-depleting therapy: hypogammaglobulinemia and impaired B-cell reconstitution","volume":"10","author":"Sacco","year":"2018","journal-title":"Immunotherapy"},{"issue":"3","key":"10.1016\/j.msard.2024.105830_bib0058","first-page":"105","article-title":"Safety and effectiveness of cladribine in multiple sclerosis: real-world clinical experience from 5 tertiary hospitals in Portugal","volume":"46","author":"Santos","year":"2023","journal-title":"Clin. Neuropharmacol."},{"issue":"3","key":"10.1016\/j.msard.2024.105830_bib0059","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/WCO.0000000000000701","article-title":"Age and the risks of high-efficacy disease modifying drugs in multiple sclerosis","volume":"32","author":"Schweitzer","year":"2019","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.msard.2024.105830_bib0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104840","article-title":"Latin American consensus recommendations on the risk of infections in people with multiple sclerosis treated with disease modifying drugs","volume":"77","author":"Silva","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2024.105830_bib0061","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104491","article-title":"Real-world experience of cladribine treatment in relapsing-remitting multiple sclerosis: a Danish nationwide study","volume":"70","author":"Sorensen","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"8","key":"10.1016\/j.msard.2024.105830_bib0062","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S1474-4422(22)00209-5","article-title":"Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial","volume":"21","author":"Svenningsson","year":"2022","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.msard.2024.105830_bib0063","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s00415-018-8812-0","article-title":"Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation","volume":"265","author":"Tallantyre","year":"2018","journal-title":"J. Neurol."},{"issue":"6","key":"10.1016\/j.msard.2024.105830_bib0064","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41582-019-0183-3","article-title":"Epidemiology and treatment of multiple sclerosis in elderly populations","volume":"15","author":"Vaughn","year":"2019","journal-title":"Nat. Rev. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2024.105830_bib0065","article-title":"Real-world treatment outcomes and safety of natalizumab in Finnish multiple sclerosis patients","volume":"9","author":"Verkkoniemi-Ahola","year":"2023","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"issue":"10","key":"10.1016\/j.msard.2024.105830_bib0066","doi-asserted-by":"crossref","first-page":"e1029","DOI":"10.1212\/WNL.0000000000007035","article-title":"The prevalence of MS in the United States: a population-based estimate using health claims data","volume":"92","author":"Wallin","year":"2019","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.msard.2024.105830_bib0067","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nrneurol.2016.21","article-title":"Disease-modifying therapies and infectious risks in multiple sclerosis","volume":"12","author":"Winkelmann","year":"2016","journal-title":"Nat. Rev. Neurol."},{"issue":"7","key":"10.1016\/j.msard.2024.105830_bib0068","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1007\/s00415-023-11700-7","article-title":"Effectiveness and safety profile of cladribine in an Italian real-life cohort of relapsing-remitting multiple sclerosis patients: a monocentric longitudinal observational study","volume":"270","author":"Zanetta","year":"2023","journal-title":"J. Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824004073?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824004073?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T07:56:56Z","timestamp":1726387016000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034824004073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":68,"alternative-id":["S2211034824004073"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2024.105830","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of high efficacy therapies in older people with Multiple Sclerosis: A real-world evidence study","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2024.105830","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105830"}}